News

Deal Announcements

BioVex Completes Fifth Venture Capital Round

Friday, November 16, 2007 5:15:00 AM PDT | VentureDeal Staff
WOBURN, MA -- Biotech company BioVex, Inc. said that it has closed the second and final closing of its series E funding round, receiving $13 million more to close the total round at $35 million.

BioVex is developing a new class of cancer treatment candidates that spread an oncolytic virus within solid tumors, causing the death of cancer cells.

Investors in the final tranche were Harris & Harris Group, Silicon Valley Bank and Oxford Financing Corporation.  The company said it will use the funds to prepare for Phase III trials of its lead candidate treatment.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1